CompletedEarly Phase 1

Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States

United States38 participantsStarted 2012-05

Plain-language summary

The goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase. Pharmacodynamic studies will also be performed in an additional cohort of 10 patients with evidence of antiphospholipid antibodies

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Estimated GFR \>35 (formula),
✓. Platelet count \>65 K/uL,
✓. Hemoglobin \>10.5 grams/dL
✓. Total bilirubin \<2.0 mg/dL

What they're measuring

AUC

Timeframe: 24 hours

Trial details

NCT IDNCT01722669

SponsorBeth Israel Deaconess Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12

Results submitted2020-04-06

View on ClinicalTrials.gov More Healthy trials